Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
50–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of probable AD according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorder Association (NINCDS-ADRDA) criteria
Mini-Mental State Examination (MMSE) score of 18-26 points at screening
Geriatric Depression Scale (GDS-15) score of \< 6
Completion of 6 years of education (or good work history consistent with exclusion of mental retardation or other pervasive developmental disorders)
If receiving concurrent AD treatment, patient must be on the medication for at least 3 months at a stable dose for at least 2 months prior to randomization.
You may not be if
Severe or unstable medical condition that, in the opinion of the investigator or Sponsor, would interfere with the patient's ability to complete the study assessments or would require the equivalent of institutional or hospital care
History or presence of clinically evident vascular disease potentially affecting the brain
History of severe, clinically significant (persistent neurologic deficit or structural brain damage) central nervous system trauma
Hospitalization within 4 weeks prior to screening
Previous treatment with MABT5102A or any other therapeutic that targets Abeta
Treatment with any biologic therapy within 5 half-lives or 3 months prior to screening, whichever is longer, with the exception of routinely recommended vaccinations, which are allowed
Clareo Health | A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
